Accéder au contenu
Merck

Bromocriptine for control of hyperthermia in a patient with mixed autonomic hyperactivity after neurosurgery: a case report.

Journal of Korean medical science (2012-08-10)
Seong Hee Kang, Min Ja Kim, Il Young Shin, Dae Won Park, Jang Wook Sohn, Young Kyung Yoon
RÉSUMÉ

Mixed autonomic hyperactivity disorder (MAHD) among patients with acquired brain injury can be rare. A delayed diagnosis of MAHD might exacerbate the clinical outcome and increase healthcare expenses with unnecessary testing. However, MAHD is still an underrecognized and evolving disease entity. A 25-yr-old woman was admitted the clinic due to craniopharyngioma. After an extensive tumor resection, she complained of sustained fever, papillary contraction, hiccup, lacrimation, and sighing. An extensive evaluation of the sustained fever was conducted. Finally, the cause for MAHD was suspected, and the patient was successfully treated with bromocriptine for a month.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
2-Bromo-α-ergocryptine methanesulfonate salt, solid
Bromocriptine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard